Abstract
Unlike mitochondria from most normal tissues, cancer cell mitochondria demonstrate an association between the glycolytic enzyme hexokinase (HK) and the voltage-dependent anion channel (VDAC). This provides a therapeutic opportunity, as the association appears to protect tumor cells from mitochondrial outer membrane permeabilization (MOMP), an event that marks the point of no return in multiple pathways leading to cell death. In this issue of Oncogene, the plant hormone methyl jasmonate (MJ) is shown to disrupt the interaction between human HK and VDAC, causing the inhibition of glycolysis and the induction of MOMP. MJ has already been shown to have selective anticancer activity in preclinical studies, and this finding may stimulate the development of a novel class of small anticancer compounds that inhibit the HK–VDAC interaction.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Latent Membrane Protein 1 Promotes Tumorigenesis Through Upregulation of PGC1β Signaling Pathway
Stem Cell Reviews and Reports Open Access 09 January 2021
-
Ischemic postconditioning confers cerebroprotection by stabilizing VDACs after brain ischemia
Cell Death & Disease Open Access 10 October 2018
-
Effect of lentivirus-mediated shRNA inactivation of HK1, HK2, and HK3 genes in colorectal cancer and melanoma cells
BMC Genetics Open Access 22 December 2016
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Adams JM, Cory S . (2007). Bcl-2-regulated apoptosis: mechanism and therapeutic potential. Curr Opin Immunol 19: 488–496.
Alcala S, Klee M, Fernandez J, Fleischer A, Pimentel-Muinos FX . (2008). A high-throughput screening for mammalian cell death effectors identifies the mitochondrial phosphate carrier as a regulator of cytochrome c release. Oncogene 27: 44–54.
Baines CP, Song CX, Zheng YT, Wang GW, Zhang J, Wang OL et al. (2003). Protein kinase Cepsilon interacts with and inhibits the permeability transition pore in cardiac mitochondria. Circ Res 92: 873–880.
Beutner G, Ruck A, Riede B, Brdiczka D . (1998). Complexes between porin, hexokinase, mitochondrial creatine kinase and adenylate translocator display properties of the permeability transition pore. Implication for regulation of permeability transition by the kinases. Biochim Biophys Acta 1368: 7–18.
Brenner C, Grimm S . (2006). The permeability transition pore complex in cancer cell death. Oncogene 25: 4744–4756.
Debatin KM, Poncet D, Kroemer G . (2002). Chemotherapy: targeting the mitochondrial cell death pathway. Oncogene 21: 8786–8803.
Ferri KF, Kroemer G . (2001). Mitochondria—the suicide organelles. Bioessays 23: 111–115.
Galluzzi L, Larochette N, Zamzami N, Kroemer G . (2006). Mitochondria as therapeutic targets for cancer chemotherapy. Oncogene 25: 4812–4830.
Goldin N, Arzoine L, Heyfets A, Israelson A, Zaslavsky Z, Bravman T et al. (2008). Methyl jasmonate binds to and detaches mitochondria-bound hexokinase. Oncogene (this issue).
Jang JY, Choi Y, Jeon YK, Kim CW . (2008). Suppression of adenine nucleotide translocase-2 by vector-based siRNA in human breast cancer cells induces apoptosis and inhibits tumor growth in vitro and in vivo. Breast Cancer Res 10: R11.
Kroemer G, Galluzzi L, Brenner C . (2007). Mitochondrial membrane permeabilization in cell death. Physiol Rev 87: 99–163.
Kroemer G, Martin SJ . (2005). Caspase-independent cell death. Nat Med 11: 725–730.
Le Bras M, Borgne-Sanchez A, Touat Z, El Dein OS, Deniaud A, Maillier E et al. (2006). Chemosensitization by knockdown of adenine nucleotide translocase-2. Cancer Res 66: 9143–9152.
Mason KD, Carpinelli MR, Fletcher JI, Collinge JE, Hilton AA, Ellis S et al. (2007). Programmed anuclear cell death delimits platelet life span. Cell 128: 1173–1186.
Miyamoto S, Murphy AN, Brown JH . (2008). Akt mediates mitochondrial protection in cardiomyocytes through phosphorylation of mitochondrial hexokinase-II. Cell Death Differ 15: 521–529.
Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al. (2005). An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435: 677–681.
Pastorino JG, Hoek JB, Shulga N . (2005). Activation of glycogen synthase kinase 3beta disrupts the binding of hexokinase II to mitochondria by phosphorylating voltage-dependent anion channel and potentiates chemotherapy-induced cytotoxicity. Cancer Res 65: 10545–10554.
Pedersen PL . (2007). Warburg, me and Hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the ‘Warburg Effect’, i.e., elevated glycolysis in the presence of oxygen. J Bioenerg Biomembr 39: 211–222.
Robey RB, Hay N . (2006). Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt. Oncogene 25: 4683–4696.
Sun L, Shukair S, Naik TJ, Moazed F, Ardehali H . (2008). Glucose phosphorylation and mitochondrial binding are required for the protective effects of hexokinases I and II. Mol Cell Biol 28: 1007–1017.
Vieira HL, Belzacq AS, Haouzi D, Bernassola F, Cohen I, Jacotot E et al. (2001). The adenine nucleotide translocator: a target of nitric oxide, peroxynitrite, and 4-hydroxynonenal. Oncogene 20: 4305–4316.
Zamzami N, El Hamel C, Maisse C, Brenner C, Munoz-Pinedo C, Belzacq AS et al. (2000). Bid acts on the permeability transition pore complex to induce apoptosis. Oncogene 19: 6342–6350.
Acknowledgements
GK is supported by Ligue contre le Cancer, Agence Nationale pour la Recherche (ANR), Cancéropôle Ile-de-France, European Commission (Active p53, Apo-Sys, Chemores, TransDeath, Right, Death-Train), and Institut National du Cancer (INCa). NT is recipient of an FRM PhD fellowship. OK is recipient of an EMBO PhD fellowship.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Galluzzi, L., Kepp, O., Tajeddine, N. et al. Disruption of the hexokinase–VDAC complex for tumor therapy. Oncogene 27, 4633–4635 (2008). https://doi.org/10.1038/onc.2008.114
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2008.114
Keywords
This article is cited by
-
MCL1 regulates AML cells metabolism via direct interaction with HK2. Metabolic signature at onset predicts overall survival in AMLs’ patients
Leukemia (2023)
-
Hexokinase II expression as a prognostic marker in diffuse large B-cell lymphoma: pre- and post-rituximab era
International Journal of Hematology (2022)
-
Latent Membrane Protein 1 Promotes Tumorigenesis Through Upregulation of PGC1β Signaling Pathway
Stem Cell Reviews and Reports (2021)
-
Ischemic postconditioning confers cerebroprotection by stabilizing VDACs after brain ischemia
Cell Death & Disease (2018)
-
Effect of lentivirus-mediated shRNA inactivation of HK1, HK2, and HK3 genes in colorectal cancer and melanoma cells
BMC Genetics (2016)